Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:23:29 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



Q:MOLN - MOLECULAR PARTNERS AG SPON ADS EACH REP 1 ORD SHS - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MOLN - Q0.21.82·4.983.03.70+0.061.62.68303.60  3.96  3.607.32  3.3215:58:4911:0015 min RT 2¢

Recent Trades - Last 10 of 30
Time ETExPriceChangeVolume
15:58:49Q3.65-0.2333
15:56:02Q3.700.06273
15:53:22Q3.750.11100
15:53:22Q3.750.11100
15:53:22Q3.700.06100
15:53:22Q3.720.08200
15:53:22Q3.70-0.182
15:37:40Q3.960.082
15:37:01Q3.960.32100
14:02:51Q3.63-0.252

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-29 11:00U:MOLNNews ReleaseMolecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action
2024-04-19 11:13U:MOLNNews ReleaseLife Science Cares Launches in Switzerland
2024-04-17 11:12U:MOLNNews ReleaseMolecular Partners Announces All Board Proposals Approved at the Annual General Meeting
2024-03-26 09:27U:MOLNNews ReleaseMolecular Partners Publishes Invitation to Annual General Meeting 2024
2024-03-14 16:00U:MOLNNews ReleaseMolecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
2024-03-01 16:00U:MOLNNews ReleaseMolecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
2024-01-07 16:00U:MOLNNews ReleaseMolecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
2024-01-05 16:00U:MOLNNews ReleaseMolecular Partners and Orano Med Announce Co-Development Agreement for ‚  Radio-DARPin Therapies
2023-12-14 01:00U:MOLNNews ReleaseMolecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences
2023-12-10 12:00U:MOLNNews ReleaseMolecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
2023-11-14 01:00U:MOLNNews ReleaseMolecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)
2023-11-03 12:00U:MOLNNews ReleaseMolecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
2023-11-02 02:00U:MOLNNews ReleaseMolecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
2023-11-01 02:00U:MOLNNews ReleaseMolecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit
2023-10-26 16:00U:MOLNNews ReleaseMolecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio
2023-09-13 01:00U:MOLNNews ReleaseMolecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting
2023-08-24 16:00U:MOLNNews ReleaseMolecular Partners Reports H1 2023 Corporate Highlights and Financials
2023-06-27 01:00U:MOLNNews ReleaseMolecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at ‚  SNMMI 2023
2023-06-19 12:00U:MOLNNews ReleaseMolecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
2023-05-25 17:01U:MOLNNews ReleaseMolecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting